The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol.127, pp.2375-90, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01800015
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature, vol.403, pp.503-514, 2000. ,
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma, Proc Natl Acad Sci, vol.100, pp.9991-9997, 2003. ,
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma, J Exp Med, vol.198, pp.851-62, 2003. ,
CHOP chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma, N Engl J Med, vol.346, pp.235-277, 2002. ,
Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and Chop chemotherapy, J Clinic Oncol, vol.17, pp.268-76, 1999. ,
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma, J Clinic Oncol, vol.19, pp.389-97, 2001. ,
Clinical impact of the cell-of-origin classification and the MYC/ BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German high-grade non-hodgkin's lymphoma study group, J Clinic Oncol, vol.35, pp.2515-2541, 2017. ,
Randomized phase III trial of Ibrutinib and Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma, J Clin Oncol, vol.37, pp.1285-95, 2019. ,
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial, Lancet Oncol, vol.20, pp.649-62, 2019. ,
Venetoclax plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) improves outcomes in BCL2-positive first-line diffuse large B-cell lymphoma (DLBCL): first safety, efficacy and biomarker analyses from the phase II CAVALLI st, Blood, vol.132, pp.782-782, 2018. ,
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing, Proceedings of the National Academy of Sciences of the United States of America, pp.3879-84, 2012. ,
Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing, Blood, vol.122, pp.1256-65, 2013. ,
Analysis of the coding genome of diffuse large B-cell lymphoma, Nat Genet, vol.43, pp.830-837, 2011. ,
Next generation sequencing in diffuse large B cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA Study, Clin Cancer Res, vol.22, pp.2919-2947, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01343064
Genome sequencing of lymphoid malignancies, Blood, vol.122, pp.3899-907, 2013. ,
Genetic heterogeneity of diffuse large B-cell lymphoma, Proc Natl Acad Sci, vol.110, pp.1398-403, 2013. ,
The molecular pathogenesis of primary mediastinal large B-cell lymphoma, Blood, vol.118, pp.2659-69, 2011. ,
Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large b cell lymphoma, Cancer Cell, vol.22, pp.359-72, 2012. ,
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways, Proceedings of the National Academy of Sciences of the United States of America, 105, pp.13520-13525, 2008. ,
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes, Nat Med, vol.24, pp.679-90, 2018. ,
Genetics and pathogenesis of diffuse large B-cell lymphoma, N Engl J Med, vol.378, pp.1396-407, 2018. ,
Genetic and functional drivers of diffuse large b cell lymphoma, Cell, vol.171, pp.481-94, 2017. ,
Integrating genome-wide genetic variations and monocyte expression data reveals trans-regulated gene modules in humans, PLoS Genet, vol.7, p.1002367, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00711658
Linear modes of gene expression determined by independent component analysis, Bioinformatics, vol.18, pp.51-60, 2002. ,
Elucidating the altered transcriptional programs in breast cancer using independent component analysis, PLoS Comput Biol, vol.3, p.161, 2007. ,
Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?, Oncotarget, vol.6, pp.16712-16736, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-02327300
Biological and clinical relevance of associated genomic alterations in MYD88 L265P and non-L265P-mutated diffuse large B-cell lymphoma: analysis of 361 cases, Clin Cancer Res, vol.23, pp.2232-2276, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01526582
Application of the cghRA framework to the genomic characterization of diffuse large B-cell lymphoma, Bioinformatics, vol.33, pp.2977-85, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02329646
GIS-TIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers, Genome Biol, vol.12, p.41, 2011. ,
Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study, J Clinic Oncol, vol.27, pp.5573-5582, 2009. ,
URL : https://hal.archives-ouvertes.fr/inserm-00424929
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study, Blood, vol.126, pp.2466-74, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-02331572
Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lympho, J Clin Oncol, vol.32, pp.3996-4003, 2014. ,
Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma, Leuk Lymph, vol.54, pp.1898-907, 2013. ,
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, J Clinic Oncol, vol.30, pp.3452-3461, 2012. ,
A library of gene expression signatures to illuminate normal and pathological lymphoid biology, Immunol Rev, vol.210, pp.67-85, 2006. ,
Molecular signatures database (MSigDB) 3.0, Bioinformatics, vol.27, pp.1739-1779, 2011. ,
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc Natl Acad Sci, vol.102, pp.15545-50, 2005. ,
The molecular signatures database hallmark gene set collection, Cell Syst, vol.1, pp.417-442, 2015. ,
Stromal gene signatures in large-b-cell lymphomas, N Engl J Med, vol.359, pp.2313-2336, 2008. ,
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray, Blood, vol.103, pp.275-82, 2004. ,
The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma, Leukemia, vol.25, pp.681-689, 2011. ,
Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma, Genes Chromosomes Cancer, vol.55, pp.251-67, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01237083
Next-generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA Study, Clin Cancer Res, vol.22, pp.2919-2947, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01343064
Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets, Leukemia, vol.32, pp.675-84, 2018. ,
Genetics of diffuse large B-cell lymphoma, Blood, vol.131, pp.2307-2326, 2018. ,
Profiling tumor infiltrating immune cells with CIBERSORT, Methods in molecular biology, pp.243-59, 2018. ,
Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL, Blood, vol.126, pp.1893-901, 2015. ,
Randomized phase 2 open-label study of R-CHOP ± Bortezomib in patients (Pts) with untreated non-germinal center B-Cell-like (Non-GCB) subtype diffuse large cell lymphoma (DLBCL): results from the pyramid trial (NCT00931918), Blood, vol.126, 2015. ,
Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma, Blood Cancer J, vol.5, p.346, 2015. ,
Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase IB study, J Clin Oncol, vol.34, pp.2698-704, 2016. ,